Please login to the form below

Not currently logged in
Email:
Password:

isavuconazole

This page shows the latest isavuconazole news and features for those working in and with pharma, biotech and healthcare.

Basilea bags $72m upfront from Pfizer for antifungal license

Basilea bags $72m upfront from Pfizer for antifungal license

Cresemba (isavuconazole) was approved in 2015 in both intravenous and oral formulations to treat adults with invasive aspergillosis and invasive mucormycosis, two life-threatening fungal infections typically seen in immunocompromised patients

Latest news

  • Rare disease therapies head the ‘class of 2015’ Rare disease therapies head the ‘class of 2015’

    isavuconazole. Cresemba. Invasive aspergillosis/mucomycosis. triazole antifungal. Basilea/Astellas. USA. ixazomib. Ninlaro. multiple myeloma.

  • Shire and Baxalta drugs among CHMP's latest recommendations Shire and Baxalta drugs among CHMP's latest recommendations

    Basilea's orphan drug Cresemba (isavuconazole), for the treatment of aspergillosis and mucormycosis - two life-threatening diseases with limited treatment options. •

  • FDA panel backs new antifungal Cresemba FDA panel backs new antifungal Cresemba

    The panel gave its blessing to Cresemba ( isavuconazole) in both intravenous and oral formulations as treatments for adults with invasive aspergillosis and invasive mucormycosis, two life-threatening fungal infections typically seen ... Isavuconazole has

  • Orphan status in US for Astellas/ Basilea antifungal Orphan status in US for Astellas/ Basilea antifungal

    Orphan status in US for Astellas/ Basilea antifungal. Isavuconazole is being developed as a treatment for invasive aspergillosis. ... Astellas and Basilea are also developing isavuconazole for candidaemia/invasive candidiasis, the most common form of

  • Pharma deals for June 2012 Pharma deals for June 2012

    This deal allows Basilea to support the regulatory filing on the antibiotic ceftobiprole for the treatment of pneumonia and to complete its phase III study for the antifungal isavuconazole (partnered with

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Basilea has granted an exclusive licence for isavuconazole (an iv and oral antifungal for invasive aspergillosis and mucomycosis) to Asahi Kasei in Japan.

  • Interview: Ken Jones, Astellas Pharma Europe Interview: Ken Jones, Astellas Pharma Europe

    We have also signed a deal with Basilea for Isavuconazole. In oncology, we've entered an agreement with AVEO Pharmaceuticals to commercialise and develop tivozanib, which has significant potential in a

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics